Clinical Trials Logo

Clinical Trial Summary

Numerous studies have recommended the use of n-3 PUFA supplementation during human pregnancy and lactation for the prevention of preterm birth, beneficial effects on fetal development, visual and cognitive development and other functional outcomes of the infants.

The aim of the present study is to assess the correlation between ratio of n-3:n-6 fatty acid and inflammation markers in SGA infants compared with appropriate for gestational age (AGA) infants. The investigators hypothesize that in SGA infants n-3 and n-6 fatty acid concentrations in cord blood will differ from those observed in AGA and might correlate with the level of circulating mediators.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Appropriate for Gestational Age Infants
  • Small for Gestational Age Infants

NCT number NCT02887664
Study type Observational
Source Tel-Aviv Sourasky Medical Center
Contact Dror Mandel, MD
Phone +97236925690
Email drorm@tlvmc.gov.il
Status Recruiting
Phase
Start date October 2, 2018
Completion date December 2020